A more accurate survey would be of all those that have tried it. If it does not work for someone, they will normally stop taking it, as it has no formal phase III trial proof baking it.Brownsfan wrote:However, the compounding pharmacy that fills my copaxone has done surveys of their LDN patients and has found that all are doing quite well.
LDN markedly reduced spasticity, while pain, fatigue and depression did not improve (or improvement didn't reach statistical significance). The study did not evaluate urinary frequency, a common symptom of MS and often reportedly helped by LDN. It should be noted that LDN is not intended for symptom improvement, but to slow down illness progression, though some patients do experience symptom relief.
During the six-month study neurological disability progressed only in one patient, which is quite a low number considering it was done on people with progressive multiple sclerosis. The study, however, was a preliminary one to assess safety and tolerability, not efficacy.
LDN was also shown to increase blood levels of beta-endorphin. Interestingly the highest levels were measured one month after cessation of the drug. Some of the symptoms were also at their lowest at this point. This raises the question whether LDN should be taken intermittently in PPMS for the best effects, but this is merely speculation.
Users browsing this forum: bitinfo